Investor Relations (IR) Questions: Rigel Pharmaceuticals RIGL
Click here to return to the biotech IRQ Index
Answers received: January 2013
Below please find answers to your questions. Thank you for your interest in Rigel Pharmaceuticals, Inc.
1) When is the last time RIGL raised cash through an offering (diluted)? October 2012
2) How much cash (not cash equivalents) does RIGL have? Rigel expects to end 2013 with cash and investments in excess of $200.0M.
3) What and approximately when is the next known catalyst? R343, an inhaled SYK inhibitor for Allergic Asthma - expect results of Ph2 study in Q3 2013.
4) What is RIGL's quarterly cash burn? Currently, Rigel does not provide quarterly guidance on burn.
5) Does RIGL have an existing line of credit and if so how much can they draw against it? No.
Below please find answers to your questions. Thank you for your interest in Rigel Pharmaceuticals, Inc.
1) When is the last time RIGL raised cash through an offering (diluted)? October 2012
2) How much cash (not cash equivalents) does RIGL have? Rigel expects to end 2013 with cash and investments in excess of $200.0M.
3) What and approximately when is the next known catalyst? R343, an inhaled SYK inhibitor for Allergic Asthma - expect results of Ph2 study in Q3 2013.
4) What is RIGL's quarterly cash burn? Currently, Rigel does not provide quarterly guidance on burn.
5) Does RIGL have an existing line of credit and if so how much can they draw against it? No.
Answers received: January 2013
Below please find answers to your questions. Thank you for your interest in Rigel Pharmaceuticals, Inc.
1) When is the last time RIGL raised cash through an offering (diluted)? (Oct 2012)
2) How much cash (not cash equivalents) does RIGL have? (guided to over $295M at the end of 2012)
3) What and approximately when is the next known catalyst? (P3 data in March/April)
4) What is RIGL's quarterly cash burn? (We don't provide quarterly guidance on burn)
5) Does RIGL have an existing line of credit and if so how much can they draw against it? (No)
Below please find answers to your questions. Thank you for your interest in Rigel Pharmaceuticals, Inc.
1) When is the last time RIGL raised cash through an offering (diluted)? (Oct 2012)
2) How much cash (not cash equivalents) does RIGL have? (guided to over $295M at the end of 2012)
3) What and approximately when is the next known catalyst? (P3 data in March/April)
4) What is RIGL's quarterly cash burn? (We don't provide quarterly guidance on burn)
5) Does RIGL have an existing line of credit and if so how much can they draw against it? (No)